Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Free Cash Flow (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Free Cash Flow for 17 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 96.67% to $5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.8 million, a 50.18% increase, with the full-year FY2025 number at -$13.8 million, up 50.18% from a year prior.
  • Free Cash Flow was $5.9 million for Q4 2025 at Myriad Genetics, down from $18.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $64.7 million in Q1 2021 to a low of -$64.7 million in Q4 2023.
  • A 5-year average of -$18.3 million and a median of -$20.1 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 533.71% in 2022, then skyrocketed 753.57% in 2025.
  • Myriad Genetics' Free Cash Flow stood at -$12.9 million in 2021, then crashed by 69.77% to -$21.9 million in 2022, then crashed by 195.43% to -$64.7 million in 2023, then soared by 104.64% to $3.0 million in 2024, then soared by 96.67% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Free Cash Flow are $5.9 million (Q4 2025), $18.3 million (Q3 2025), and -$16.4 million (Q2 2025).